Volume 18, Number 1—January 2012
Letter
Mumps Vaccine Effectiveness Against Orchitis
Susan Hahné
, Jane Whelan, Rob van Binnendijk, Corien Swaan, Ewout Fanoy, Hein Boot, and Hester E. de Melker
, Jane Whelan, Rob van Binnendijk, Corien Swaan, Ewout Fanoy, Hein Boot, and Hester E. de Melker
Table
Mumps complications by MMR vaccination status, the Netherlands, December 1, 2009–June 14, 2011*
| Complication | MMR doses received | No. mumps cases | No. (%) cases with complications | OR | aOR† | p value | Adjusted VE,‡ % (95% CI) |
|---|---|---|---|---|---|---|---|
| Orchitis§ | 0 | 86 | 20 (23) | Ref | Ref | Ref | Ref |
| 1 | 48 | 5 (10) | 0.38 | 0.34 | 0.05 | 66 (1 to 88) | |
| 2 | 338 | 31 (9) | 0.32 | 0.26 | <0.01 | 74 (49 to 87) | |
| Other complications¶ | 0 | 117 | 1 (1) | Ref | Ref | Ref | Ref |
| 1 | 85 | 1 (1) | 1.38 | 0.88 | 0.93 | 12 (–14 to 95) | |
| 2 | 571 | 6 (1) | 1.23 | 0.75 | 0.80 | 25 (–5 to 91) | |
| Hospitalization | 0 | 130 | 4 (3) | Ref | Ref | Ref | Ref |
| 1 | 83 | 2 (2) | 0.80 | 0.70 | 0.69 | 30 (–312 to 88) | |
| 2 | 535 | 6 (1) | 0.40 | 0.43 | 0.25 | 57 (–84 to 90) |
*Only those for whom complication and vaccination status were known are included; therefore, totals may differ. MMR, mumps, measles, rubella; OR, odds ratio; aOR, adjusted odds ratio; VE, vaccine effectiveness; ref, reference categories.
†OR and VE adjusted for age group (<18, 18−25, >25 y) and sex, except for orchitis, where the OR and VE were adjusted only for age group.
‡VE = 1 – OR where the OR is an approximation of the relative risk.
§Only men ≥12 years of age are included.
¶Includes the following reported complications: pancreatitis (n = 2), meningitis (3), thyroiditis (1), bronchitis (1), high fever and shortness of breath (1).
Page created: December 22, 2011
Page updated: December 22, 2011
Page reviewed: December 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.